Abstract. MicroRNAs (miRNAs) that negatively regulate gene expression play a key role in the development and progression of cancer. Aberrant expression of hsa-miR-187 (miR-187) has been reported in various malignancies. However, the function of miR-187 in tumor progression remains controversial and its role in non-small cell lung cancer (NSCLC) is poorly understood. In the present study, the role of miR-187 in the progression of NSCLC was investigated. Our results revealed that miR-187 was frequently upregulated in NSCLC tissues and cells. Furthermore, ectopic introduction of miR-187 promoted cell migration, whereas miR-187 inhibitor had the contrary effect in NSCLC cells. Of significance, miR-187 induced epithelial-mesenchymal transition (EMT), which plays a pivotal role in the initiation of metastasis and activated mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways. Polymerase I and transcript release factor (PTRF) was identified as a direct target of miR-187 in the promotion of the migration of NSCLC cells. Restored expression of PTRF neutralized the promoting effect of miR-187 on cell migration and EMT of NSCLC cells. Collectively, our data highlight the pivotal role of miR-187 in the progression of NSCLC, indicating this factor as a potential candidate in molecular cancer therapy.
Introduction
Lung cancer remains the leading cause of cancer-related deaths worldwide (1) . Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer subtypes and its clinical course is very crucial with poor patient outcomes (2, 3) . Despite recent advances in chemotherapy and surgical procedures, the overall 5-year survival rate of NSCLC patients (~15%) has not markedly improved (1) . Adjacent invasion and distant metastases are responsible for the failure of lung cancer therapy (4) . Therefore, further exploration of the underlying mechanisms of NSCLC progression is essential.
Epithelial-mesenchymal transition (EMT) is a key stage in tumor progression. This biological process permits polarized epithelial cells to assume a mesenchymal cell phenotype, however this often induces tumor metastasis (5) . Increasing evidence supports EMT as a common event in human advanced NSCLC (6, 7) . Consequently, to identify new diagnostic strategies and specifically targeted drugs, exploring key molecules in EMT that control NSCLC metastasis is paramount.
MicroRNAs (miRNAs), a family of small non-coding RNAs, are processed from precursor RNAs with a typical hairpin secondary structure (8) . Several miRNAs are aberrantly expressed in NSCLC and their dysregulation has resulted in cancer progression and poor clinical outcome (9) (10) (11) . Considering that miRNAs usually act as EMT-associated downstream effectors of receptor signaling or protein kinases (12) , miRNAs may represent novel targets for designing antimetastatic drugs due to their specificity. Moreover, miRNA efficacy data is now available, making miRNA-based technology applicable against NSCLC metastasis in vivo (13) .
Recently, miR-187 ectopic expression was detected in various types of cancer including nasopharyngeal (14) , renal (15) , pancreatic (16) , prostate (17) and neuroblastoma (18) . In NSCLC, miR-187 is also a potential tumor suppressor (19) , however the precise molecular mechanism through which miR-187 influences NSCLC progression remains largely unknown. In the present study, we aimed to investigate the MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer potential role of miR-187 in NSCLC progression. We also explored the mechanisms underlying tumor metastasis and direct targets of miR-187.
Materials and methods
Cell culture. Human NSCLC cell lines A549, H322, GLC-82, SPC-A1, PC-9, H460 and H1299, and the normal human bronchial epithelial cell line BEAS-2B, were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were authenticated by short tandem repeat (STR) profiling before receipt and were propagated for <6 months after resuscitation. All cells were cultured in RPMI-1640 medium (HyClone, Logan, uT, uSA) supplemented with 10% fetal bovine serum (FBS; Gibco-BRL, Invitrogen, Paisley, uK) at room temperature with a humidity of 90-95%, and 5% CO 2 .
miRNA transfection. Refer to our previous study for details (20) .
Microarray data set analysis. A microarray data set containing 116 paired primary lung cancers, and their corresponding adjacent normal lung tissues (collected a minimum of 5 cm from the tumor) were retrieved from the Gene Expression Omnibus (GEO) database (accession no. GSE15008) (21) .
RNA isolation, reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR).
qRT-PCR for miRNAs and target genes was performed as previously described (20, 22 
Immunofluorescence (IF).
Refer to our previous study for details (20) . In brief, slides were incubated with a rabbit antibody to E-cadherin, mouse antibodies to β-catenin and vimentin (1:500; Santa Cruz Biotechnology), and rabbit antibody to PTRF (1:100; Abcam) at 4̊C overnight followed by washing with phosphate-buffered saline (PBS) 3 times. Coverslips were then incubated with fluorescein isothiocyanate (FITC)-or Texas Red (TR)-conjugated anti-mouse or anti-rabbit secondary antibodies (1:120; Santa Cruz Biotechnology) for 30 min at room temperature prior to staining with 4'-6-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA, uSA).
Cell migration analysis. Refer to our previous study for details (20) .
Wound-healing assay. Refer to our previous study for details (20) .
miRNA target validation. The full-length PTRF 3' untranslated regions (3'UTRs) were amplified by PCR and cloned downstream of the firefly luciferase gene in the psiCHECK-2 vector (Promega, Madison, WI, uSA). This vector was named the wild-type (wt) 3'uTR. Site-directed mutagenesis of the miR-187 binding site in the PTRF 3'uTR was conducted with the GeneTailor Site-Directed Mutagenesis System (Invitrogen) and named the mutant (mt) 3'uTR. For reporter assays, the wt or mt 3'uTR and miR-187 mimic or inhibitor were cotransfected. The luciferase activity was assessed 2 days after transfection using the Dual-Luciferase Reporter Assay System (Promega). Primer sequences used for PCR assays were as follows: WT PTRF forward, 5'-CCGCTCGAGGAGGCAGCCCCCG CAGTGGACAAC-3' and reverse, 5'-ATAAGAATGCGGCC GCGAAAAGCAGGTTTATTGGTCGGGC-3'; MutPTRF-1 forward, 5'-TGATTCTGTTTGGACTGGGTTCTCATCTGT GCTCCAGGTTCTCAAGACACGAGTCCCC-3' and reverse 5'-GGGGACTCGTGTCTTGAGAACCTGGAGCACAGAT GAGAACCCAGTCCAAACAGAATCA-3'; MutPTRF-2 forward, 5'-TTCTCAAGACACGACCAGGTTCTCATCTGT GCTGTCCCCTTGTTCCTCCCCATTAAAG-3' and reverse 5'-CTTTAATGGGGAGGAACAAGGGGACAGCACAGAT GAGAACCTGGTCGTGTCTTGAGAA-3'; and MutPTRF-3 forward, 5'-TTCTCATCTGTGCTCCAGGTTCTCATCTGT GCTGTCCCCTTGTTCCTCCCCATTAAAG-3' and reverse 5'-CTTTAATGGGGAGGAACAAGGGGACAGCACAGAT GAGAACCTGGAGCACAGATGAGAA-3' . Statistical analysis. Data were analyzed using SPSS software (version 19.0; SPSS, Inc., Chicago, IL, uSA). For the qRT-PCR, Transwell and luciferase reporter assays, the Student's t-test or one-way analysis of variance (ANOVA) was carried out. All data are presented as the mean ± standard deviation (SD). Statistical significance was established when the P-value was <0.05.
Results

miR-187 is upregulated in NSCLC tissues and cell lines.
Microarray analysis showed that miR-187 was upregulated at an average of 1.26-fold (P=0.0018) in the primary lung neoplasms compared with the corresponding adjacent normal lung tissues. up to a 4.99-fold change in miR-187 expression was found in 71 of all 116 NSCLC samples compared to the controls (Fig. 1A) . Furthermore, increased expression of miR-187 was found in all 7 NSCLC cell lines compared with the normal human bronchial epithelial cell line BEAS-2B (Fig. 1B) .
Exogenous miR-187 promotes NSCLC cell migration and motility in vitro.
In the present study, miR-187 mimic oligonucleotides were transfected into A549 and GLC-82 cell lines to determine their effects on cellular behavior. In contrast, anti-miR-187 was utilized to observe the effect of miR-187-depletion on cellular behavior as an miRNA inhibitor. qRT-PCR was performed to detect the transfection efficiency (P<0.05; Fig. 2A ). miR-187-treated cells showed a remarkable increase in migration and motility potential in Transwell and wound-healing assays, whereas depletion of endogenous miR-187 significantly decreased migration and motility (P<0.05; Fig. 2B and C) .
miR-187 mediates EMT and activates signal transduction pathways.
To investigate the mechanisms underlying miR-187-mediated biological behavior, we investigated its effects on EMT and signal transduction pathways. IF assays revealed that exogenous miR-187 overexpression resulted in decreased expression of the epithelial markers E-cadherin and β-catenin, and increased expression of the mesenchymal marker vimentin (Fig. 3A) . Western blot analysis revealed similar changes in EMT markers (Fig. 3B) and indicated that the phosphorylation status of proteins was involved in EMT signaling. As shown in Fig. 3C , miR-187 activated the mitogen-activated protein kinase (MAPK) pathway through the phosphorylation of p44/42 MAPK (ERK1/2) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling via the phosphorylation of AKT in A549 and GLC-82 cells.
PTRF is a direct target of miR-187. As indicated by computer-based sequence analysis (based on TargetScan Human 6.2, PicTar and miRanda), PTRF was identified as a potential target of miR-187 and therefore considered to be involved in cell migration. The target sequence (wt 3'uTR) or 2 mutant sequences (mt 3'uTR position 1764-1790) were cloned into a luciferase reporter vector (Fig. 4A) , then 293T cells were transfected with the wt or mt 3'uTR vector and an miR-187 mimic. A significant decrease in luciferase activity was observed in both the wt and mt vectors compared with the miR controls, whereas increased activity was found in cells cotransfected with anti-miR-187 and the wt or mt 3'uTR vectors (Fig 4B) . unlike for double mutations, single mutations in the putative binding sites in the PTRF 3'uTR region could not abrogate this suppression, thereby providing strong evidence of direct interaction between miR-187 and PTRF (Fig. 4B) . In general, these results strongly suggest that PTRF is a direct target of miR-187 in NSCLC cells. Additionally, qRT-PCR revealed decreased expression of PTRF in A549 and GLC-82 cells transfected with miR-187 (Fig. 4C) . Western blot analysis revealed that transfection of miR-187 led to a markedly decreased expression of PTRF proteins in NSCLC cells (Fig. 4D ), which were confirmed by IF assays to be potential target genes regulated by miR-187 (Fig. 4E) .
PTRF plays crucial roles in miR-187-induced EMT and migration of NSCLC cells.
To further explore the function and role of PTRF in NSCLC, we performed gain-of-function assays. Relatively decreased expression of PTRF was found in H460, GLC-82, SPC-A1 and A549 NSCLC cell lines compared with the normal human bronchial epithelial cell line BEAS-2B (Fig. 5A) . Exogenous introduction of PTRF markedly enhanced PTRF protein expression (Fig. 5B) and decreased the capacity of cell migration in A549 and GLC-82 cells (Fig. 5C) .
To evaluate the biological role of PTRF in cell migration and EMT induced by miR-187, we rescued PTRF expression in miR-187-transfected NSCLC cells by transfection with PTRF ORF constructs without 3'uTRs. The results revealed that exogenous introduction of PTRF clearly suppressed miR-187-induced promotion of migratory potential in A549 and GLC-82 cells (Fig. 6A) . Consistent with the biological phenotype results, re-expression of PTRF recovered miR-187-induced EMT (Fig. 6B) , strongly supporting PTRF as a key mediator of miR-187-induced cell migration.
Discussion
Our present results highlight the importance of upregulated miR-187 expression for NSCLC cells to develop and/or sustain their aggressive phenotype. Aberrant expression of miR-187 has been reported in various types of cancer (14) (15) (16) (17) (18) . Although changes in expression vary greatly, miR-187 may participate in tumorigenesis in a tissue-specific manner. However, data on the effects of miR-187 in tumor progression are controversial. For example, in one study, antisense-induced suppression of miR-187 caused the inhibition of cell viability in HeLa cells (23) , whereas overexpression of miR-187 induced apoptosis and led to decreased proliferation of HeLa cells in another study (24) . Hence, enriching our knowledge regarding specific tumors may contribute to better clinical management. In NSCLC, miR-187 was found to be a potential tumor suppressor in tumor development (19) , but the precise molecular mechanism through which miR-187 influences NSCLC progression remains largely unknown. In the present study, miR-187 was demonstrated to be a potential promoter of NSCLC progression. However, the mechanism underlying the abnormal expression of miR-187 remains unclear. The present data did not support that abnormal histone or DNA methylation was involved in abnormal expression. Our previous data revealed that miR-187 may be regulated by cell factors in colorectal cancer (CRC), such as transforming growth factor-β (TGFβ). Numerous recent studies have revealed that signaling pathways or non-coding RNAs also regulate miRNA expression (25, 26) . We may investigate the regulatory mechanism of miR-187 in more detail in future studies.
The mechanism underlying the relationship between miR-187 and tumor aggressiveness remains to be elucidated. EMT is a critical step in tumor progression. Recently, the role of miRNAs in EMT has become a focus in the field of cancer research. Several studies have demonstrated that miR-200 family members act as key regulators of EMT to enforce the epithelial phenotype (27) . The suppressive role of miR-187 in ovarian cancer cell lines promoted EMT and was reported to be achieved through targeting of disabled homolog 2 (Dab2) to decrease migration and E-cadherin expression (28) . However, these are currently the only observations and suggestions for the underlying molecular mechanisms. In the present study, miR-187 suppressed the epithelial phenotype and induced mesenchymal transition, strongly suggesting its critical role in the EMT process.
TGFβ is a known inducer of EMT via Smads and complementary non-Smad pathways, such as MAPK (29) (30) (31) and PI3K/AKT (32) (33) (34) . In our previous study, miR-187 suppressed not only the Smad pathway but also non-Smad pathways in CRC. Restoring expression of miR-187 only partially neutralized TGFβ-mediated activation of the Smad pathway by decreasing the phosphorylation level of Smad2 (20) . In NSCLC, our data revealed that miR-187 could activate both the MAPK and PI3K/AKT pathways, implying that miR-187 induced NSCLC cell EMT via a non-Smad pathway, not the classical Smad pathway. Therefore, downstream targets must be explored in miR-187-induced EMT, and may be useful in designing novel specific targeted drugs for managing NSCLC metastasis. However, the specific regulator of miR-187 as a metastasis promoter is still unclear.
In general, miRNAs exert their biological function by suppressing their specific target genes at the post-transcriptional level. Recently, B7-H3 (a novel member of the B7 family) and Dab2 were reported as target genes of miR-187 in renal and ovarian cancers, respectively (15, 28) . SOX4, NT5E and PTK6 expression was increased in CRC cells treated with TGFβ, and these effects were offset by the addition of miR-187, suggesting that they are required for TGFβ-induced EMT (20) . However, we were not able to identify them as targets directly regulated by miR-187 in NSCLC. As previously mentioned, miR-187 may act in a cell-or organ-specific manner through the alteration of the expression of target genes, further changing their phenotypes. In the present study, all the evidence indicates that PTRF may be a direct target of miR-187. Rescued expression of PTRF restored the effect of miR-187 treatment and inactivated the downstream pathway.
PTRF, also known as cavin-1, was originally identified as a protein involved in the dissociation of transcription complexes in vitro (35) . PTRF in the cell surface membrane is associated with vesicular transport, cholesterol homeostasis (36, 37) and lipolysis control (38) . To date, the majority of studies related to PTRF have focused on prostate cancer (PC). Changes in the cell membrane involving loss of PTRF expression occur with the development of PC (39) . Overexpression of PTRF in PC3 cells decreased cell motility by decreasing matrix metalloprotease 9 (MMP9) production (40) . The absence of PTRF in PC cells was found to contribute significantly to tumor progression and metastasis by promoting the angiogenesis and lymphangiogenesis potential of cancer cells (41) . One study supports a role for PTRF/cavin-1, through caveolae formation, as an attenuator of the non-caveolar functionality of Cav1 in Gal3-Cav1 signaling and regulation of focal adhesion dynamics and cancer cell migration (42) . In addition, loss of PTRF expression has been demonstrated to be related with tumor progression in breast (43) , pancreatic (44) and glioblastoma (33) cancers. Only one publication based on proteomic assays reported PTRF/cavin-1 loss-of-expression in NSCLC tissue at the protein level, suggesting a potential role for PTRF in NSCLC development (45) . Our results demonstrated for the first time that PTRF contributes to NSCLC progression through its involvement in EMT development.
In short, our results provide a basis for the concept that increased expression of miR-187 in human NSCLC may be significant in the acquisition of an aggressive phenotype. We believe that miR-187 functions as a promoter in NSCLC progression and may serve as a novel therapeutic biomarker. Moreover, the functional and/or mechanistic studies of miR-187 presented in the present study, indicate that miR-187 may play a critical role in controlling non-Smad-mediated EMT by regulating PTRF expression. This suggests that activating EMT during tumor metastasis in NSCLC may be counteracted by suppressing miR-187, a notion that can be readily tested in the clinic.
